BioVersys AG (XSWX:BIOV) Total Operating Expense: CHF16.87 Mil (TTM As of Dec. 2025)


XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF27.00
View Full Analysis

What is BioVersys AG Total Operating Expense?

BioVersys AG XSWX:BIOV 4 Total Operating Expense is CHF16.87 Mil as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100.

BioVersys AG's Total Operating Expense for the six months ended in Dec. 2025 was CHF9.93 Mil. BioVersys AG's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was CHF16.87 Mil.

BioVersys AG Total Operating Expense Related Terms

BioVersys AG Total Operating Expense Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Total Operating Expense Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Total Operating Expense
14.77 16.87

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Total Operating Expense 8.07 6.70 6.94 9.93
XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF16.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of CHF16.87 Mil mean?
BioVersys AG (XSWX:BIOV) has a Total Operating Expense of CHF16.87 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on BioVersys AG and its competitors.
Is BioVersys AG's Total Operating Expense too high?
BioVersys AG's current Total Operating Expense is CHF16.87 Mil. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Total Operating Expense compare to VRTX and REGN?
BioVersys AG's Total Operating Expense of CHF16.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on BioVersys AG and its competitors. BioVersys AG's current Total Operating Expense is CHF16.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Total Operating Expense of CHF16.87 Mil. The current Total Operating Expense is CHF16.87 Mil. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Total Operating Expense is CHF16.87 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF27.00
Price